UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE 13d-2(a)
(Amendment No. ___)*
Durata Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.01 per share
(Title of Class of Securities)
26658A 10 7
(CUSIP Number)
Lloyd Appel
Aisling Capital
888 Seventh Avenue, 30th Floor
New York, NY 10106
(212) 651-6380
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
July 24, 2012
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 26658A 10 7 | SCHEDULE 13D | Page 2 of 14 |
| 1 | NAME OF REPORTING PERSON OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Aisling Capital III, LP | |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) x |
| 3 | SEC USE ONLY | |
| 4 | SOURCE OF FUNDS OO | |
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) | o |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 3,130,824 |
8 | SHARED VOTING POWER 0 | |
9 | SOLE DISPOSITIVE POWER 3,130,824 | |
10 | SHARED DISPOSITIVE POWER 0 |
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,130,824 | |
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | o |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 18.2% (1) | |
| 14 | TYPE OF REPORTING PERSON PN |
(1) | Based on 17,240,363 shares of the Issuer’s common stock issued and outstanding following the initial public offering of the Issuer’s common stock, as reported in the Issuer’s final prospectus filed with the Securities Exchange Commission (the “SEC”) on July 20, 2012. |
CUSIP No. 26658A 10 7 | SCHEDULE 13D | Page 3 of 14 |
| 1 | NAME OF REPORTING PERSON OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Aisling Capital Partners III, LP | |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) x |
| 3 | SEC USE ONLY | |
| 4 | SOURCE OF FUNDS OO | |
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) | o |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 3,130,824 |
8 | SHARED VOTING POWER 0 | |
9 | SOLE DISPOSITIVE POWER 3,130,824 | |
10 | SHARED DISPOSITIVE POWER 0 |
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,130,824 | |
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | o |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 18.2% (1) | |
| 14 | TYPE OF REPORTING PERSON PN |
| (1) | Based on 17,240,363 shares of the Issuer’s common stock issued and outstanding following the initial public offering of the Issuer’s common stock, as reported in the Issuer’s final prospectus filed with the SEC on July 20, 2012. |
CUSIP No. 26658A 10 7 | SCHEDULE 13D | Page 4 of 14 |
| 1 | NAME OF REPORTING PERSON OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Aisling Capital Partners III LLC | |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) x |
| 3 | SEC USE ONLY | |
| 4 | SOURCE OF FUNDS OO | |
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) | o |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 3,130,824 |
8 | SHARED VOTING POWER 0 | |
9 | SOLE DISPOSITIVE POWER 3,130,824 | |
10 | SHARED DISPOSITIVE POWER 0 |
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,130,824 | |
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | o |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 18.2% (1) | |
| 14 | TYPE OF REPORTING PERSON OO |
| (1) | Based on 17,240,363 shares of the Issuer’s common stock issued and outstanding following the initial public offering of the Issuer’s common stock, as reported in the Issuer’s final prospectus filed with the SEC on July 20, 2012. |
CUSIP No. 26658A 10 7 | SCHEDULE 13D | Page 5 of 14 |
| 1 | NAME OF REPORTING PERSON OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Steve Elms | |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) x |
| 3 | SEC USE ONLY | |
| 4 | SOURCE OF FUNDS OO | |
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) | o |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 0 |
8 | SHARED VOTING POWER 3,130,824 | |
9 | SOLE DISPOSITIVE POWER 0 | |
10 | SHARED DISPOSITIVE POWER 3,130,824 |
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,130,824 | |
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | o |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 18.2% (1) | |
| 14 | TYPE OF REPORTING PERSON IN |
| (1) | Based on 17,240,363 shares of the Issuer’s common stock issued and outstanding following the initial public offering of the Issuer’s common stock, as reported in the Issuer’s final prospectus filed with the SEC on July 20, 2012. |
CUSIP No. 26658A 10 7 | SCHEDULE 13D | Page 6 of 14 |
| 1 | NAME OF REPORTING PERSON OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Dennis Purcell | |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) x |
| 3 | SEC USE ONLY | |
| 4 | SOURCE OF FUNDS OO | |
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) | o |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION United States |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 0 |
8 | SHARED VOTING POWER 3,130,824 | |
9 | SOLE DISPOSITIVE POWER 0 | |
10 | SHARED DISPOSITIVE POWER 3,130,824 |
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,130,824 | |
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | o |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 18.2% (1) | |
| 14 | TYPE OF REPORTING PERSON IN |
| (1) | Based on 17,240,363 shares of the Issuer’s common stock issued and outstanding following the initial public offering of the Issuer’s common stock, as reported in the Issuer’s final prospectus filed with the SEC on July 20, 2012. |
CUSIP No. 26658A 10 7 | SCHEDULE 13D | Page 7 of 14 |
| 1 | NAME OF REPORTING PERSON OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Andrew Schiff | |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) x |
| 3 | SEC USE ONLY | |
| 4 | SOURCE OF FUNDS OO | |
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) | o |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION United States |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 0 |
8 | SHARED VOTING POWER 3,130,824 | |
9 | SOLE DISPOSITIVE POWER 0 | |
10 | SHARED DISPOSITIVE POWER 3,130,824 |
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,130,824 | |
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | o |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 18.2% (1) | |
| 14 | TYPE OF REPORTING PERSON IN |
| (1) | Based on 17,240,363 shares of the Issuer’s common stock issued and outstanding following the initial public offering of the Issuer’s common stock, as reported in the Issuer’s final prospectus filed with the SEC on July 20, 2012. |
CUSIP No. 26658A 10 7 | SCHEDULE 13D | Page 8 of 14 |
| Item 1. | Security and Issuer. |
The security to which this statement relates is common stock, par value $0.01 per share (the “Common Stock”). The principal executive offices of Durata Therapeutics, Inc. (the “Issuer”) are located at 89 Headquarters Plaza North, 14th Floor, Morristown, New Jersey 07960.
| Item 2. | Identity and Background. |
(a) This Schedule 13D is being filed on behalf of the following persons (each, a “Reporting Person” and collectively, the “Reporting Persons”):
| (i) | Aisling Capital III, LP (“Aisling”); |
| (ii) | Aisling Capital Partners III, LP (“Aisling Partners”), the general partner of Aisling; |
| (iii) | Aisling Capital Partners III LLC (“Aisling Partners GP”) the general partner of Aisling Partners; |
| (v) | Mr. Dennis Purcell, a managing member of Aisling Partners GP; |
| (vi) | Mr. Steve Elms, a managing member of Aisling Partners GP; |
| (vi) | Mr. Andrew Schiff, a managing member of Aisling Partners GP (together with Mr. Dennis Purcell and Mr. Steve Elms, the “Managers”). |
(b) The principal business address for each of the Reporting Persons is 888 Seventh Avenue, 30th Floor, New York, New York 10106.
(c) Aisling was formed in order to engage in the acquiring, holding and disposing of investments in various companies. Aisling Partners is the general partner of Aisling and was formed to act as the general partner of Aisling, to make investments through Aisling and to fulfill such other purposes as may be determined by Aisling from time to time. Aisling Partners GP is the general partner of Aisling Partners and was formed to act as the general partner of Aisling Partners. Dennis Purcell, Steve Elms and Andrew Schiff are the Managers of Aisling Partners GP. Accordingly, pursuant to the regulations promulgated under Section 13(d) of the Securities Exchange Act of 1934, Aisling Partners, Aisling GP, Mr. Elms, Mr. Purcell and Mr. Schiff each may be deemed to be a beneficial owner of the Common Stock held for the account of Aisling.
CUSIP No. 26658A 10 7 | SCHEDULE 13D | Page 9 of 14 |
(d) None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e) None of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding were or are subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws.
(f) Each of Aisling and Aisling Partners is a Delaware limited partnership. Aisling Partners GP is a Delaware limited liability company. Each of Steven Elms, Dennis Purcell and Andrew Schiff is a United States citizen.
| Item 3. | Source and Amount of Funds or Other Consideration. |
As of the date hereof, each of the Reporting Persons may be deemed to beneficially own 3,130,824 shares of Common Stock, consisting of (i) 1,111,111 shares of Common Stock, which were acquired on July 24, 2012 in the Issuer’s initial public offering of Common Stock (“IPO”) with an aggregate purchase price of $9,999,999 and (ii) 2,019,713 shares of Common Stock issued upon the conversion of 16,157,707 shares of Series A Preferred Stock (“Series A Preferred Stock”) at the closing of the IPO on July 24, 2012 (the “Conversion”). The source of the purchase price for the Purchase was capital contributions from the partners of Aisling. No borrowed funds were used to purchase the Common Stock.
| Item 4. | Purpose of Transaction. |
Each Reporting Person expects to evaluate on an ongoing basis the Issuer’s financial condition and prospects and its interest in, and intentions with respect to, the Issuer and their investment in the securities of the Issuer, which review may be based on various factors, including the Issuer’s business and financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer’s securities in particular, as well as other developments and other investment opportunities, which, if effected, could result in, among other things, any of the matters identified in Items 4(a)−(j) of Schedule 13D. Accordingly, each Reporting Person reserves the right to change its intentions and develop plans or proposals at any time, as it deems appropriate. In particular, each Reporting Person may at any time and from time to time, (i) in the open market, in privately negotiated transactions or otherwise, acquire additional Common Stock or other
CUSIP No. 26658A 10 7 | SCHEDULE 13D | Page 10 of 14 |
securities of the Issuer, including acquisitions from affiliates of the Reporting Persons; (ii) dispose or transfer of all or a portion of the securities of the Issuer, including the Common Stock, that the Reporting Persons now own or may hereafter acquire to any person or entity, including dispositions to affiliates of the Reporting Persons; (iii) enter into derivative transactions with institutional counterparties with respect to the Issuer’s securities; (iv) cause or seek to cause the Issuer or any of its subsidiaries to acquire all or a portion of another person's assets or business, including acquisitions from affiliates of the Reporting Persons; (v) cause or seek to cause the Issuer or any of its subsidiaries to enter into one or more acquisitions, business combinations or mergers or to sell, transfer or otherwise dispose of all or any portion of its assets or business to any person or entity, including acquisitions, business combinations, mergers, sales, transfers and other dispositions with or to affiliates of the Reporting Persons; (vi) restructure the Issuer’s or any of its subsidiaries’ capitalization, indebtedness or holding company arrangements; (vii) make personnel changes to the present management of the Issuer deemed necessary or desirable; (viii) change the identity of the directors of the Issuer; (ix) make or propose any other material change in the Issuer’s or any of its subsidiaries’ corporate structure or business; or (x) engage in communications with one or more stockholders, officers or directors of the Issuer and other persons regarding any of the matters described in clauses (i) through (ix) above.
| Item 5. | Interest in Securities of the Issuer. |
(a) The aggregate percentage of shares of Common Stock reported as owned by each Reporting Person is based on 17,240,363 shares of the Issuer’s common stock issued and outstanding following the IPO, as reported in the Issuer’s final prospectus filed with the SEC on July 20, 2012. Based on calculations made in accordance with Rule 13d-3(d), each Reporting Person may be deemed to beneficially own 3,130,824 shares of Common Stock constituting approximately 18.2% of the outstanding shares of Common Stock.
(b) (i) Each of Aisling, Aisling Partners and Aisling Partners GP may be deemed to have sole power to direct the voting and disposition of the 3,130,824 shares of Common Stock that may be deemed to be beneficially owned by the Reporting Persons.
(ii) By virtue of the relationships between and among the Reporting Persons described in Item 2 of this Schedule 13D, each of the Messrs. Elms, Purcell and Schiff may be deemed to share the
CUSIP No. 26658A 10 7 | SCHEDULE 13D | Page 11 of 14 |
power to direct the voting and disposition of the 3,130,824 shares of Common Stock beneficially owned by the Reporting Persons.
(c) On July 20, 2012, Aisling acquired (i) 1,111,111 shares of Common Stock in the IPO with an aggregate purchase price of $9,999,999 at $9.00 per share and (ii) 2,019,713 shares of Common Stock issued upon the Conversion.
(d) The partners of Aisling have the right to participate in the receipt of dividends from, or proceeds from the sale of, the shares of Common Stock held for the account of Aisling in accordance with their ownership interests in Aisling.
(e) Not applicable.
| Item 6. | Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. |
On July 18, 2012, Aisling signed a letter for the benefit of Merrill Lynch, Pierce, Fenner & Smith Incorporated and Credit Suisse Securities (USA) LLC as representatives of the several underwriters named in the underwriting agreement in connection with the IPO (collectively, the “Underwriters”) and confirmed and agreed to not sell, transfer, assign, pledge or hypothecate 1,111,111 shares of Common Stock acquired in the IPO until October 18, 2012.
On March 21, 2012, Aisling entered into a lock-up agreement with Merrill Lynch, Pierce, Fenner & Smith Incorporated and Credit Suisse Securities (USA) LLC as representatives of the Underwriters and agreed that until September 17, 2012 it will not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant for the sale of, or otherwise dispose of or transfer, directly or indirectly, any shares of Common Stock or securities convertible into or exchangeable or exercisable for any shares of Common Stock, including 2,019,713 shares of Common Stock issued upon the Conversion (the “Locked-up Securities”) or exercise any right with respect to the registration of the Locked-up Securities or the filing of any registration statement in connection therewith, under the Securities Act of 1933, as amended; or (ii) enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Locked-up Securities. Such restrictions do not apply, subject to certain conditions, to transactions relating to (i) bona fide gifts, (ii) transfers to a family member or a trust, (iii) a
CUSIP No. 26658A 10 7 | SCHEDULE 13D | Page 12 of 14 |
distribution to limited partners, members or stockholders of Aisling or to Aisling’s affiliates or to any investment fund or other entity controlled or managed by Aisling or (iv) transfers by will.
Pursuant to the Investor Rights Agreement (the “Investor Rights Agreement”), dated December 9, 2009, by and among the Issuer and the holders of Common Stock issuable upon the Conversion listed in Schedule A thereto, including Aisling (the “Holders”), the Issuer may be required to register under the Securities Act of 1933, as amended (the “Securities Act”), 2,019,713 shares of Common Stock held by Aisling issued upon the Conversion. Pursuant to the Investors Rights Agreement, (i) beginning September 17, 2012, upon a written request to the Issuer from any Holder or Holders of at least 75% of the Registrable Securities (as defined in the Investors Rights Agreement), the Issuer is required to register all or a portion of such Holder’s or Holders’ shares on any registration statement (other than on Form S-3 unless the Issuer becomes eligible to use Form S-3 as further described below) if the anticipated aggregate offering price is at least $10,000,000; (ii) any Holder or Holders may request the Issuer to register its or their shares on Form S-3 if the anticipated aggregate offering price is at least $1,000,000; and (iii) if at any time the Issuer determines to register any of its securities, it is required to promptly notify all Holders and include in such registration, or “piggy-back,” all the Registrable Securities requested by any Holder or Holders. The Issuer will pay any registration expenses relating to the registration rights of the Holders, subject to certain conditions. The registration rights described above will terminate on July 18, 2018. The Investor Rights Agreement contains customary indemnification and contribution provisions.
From time to time, each of the Reporting Persons may lend portfolio securities to brokers, banks or other financial institutions. These loans typically obligate the borrower to return the securities, or an equal amount of securities of the same class, to the lender and typically provide that the borrower is entitled to exercise voting rights and to retain dividends during the term of the loan. From time to time, to the extent permitted by applicable laws, each of the Reporting Persons may borrow securities, including the Common Stock, for the purpose of effecting, and may effect, short sale transactions, and may purchase securities for the purpose of closing out short positions in such securities.
On July 25, 2012, each of the Reporting Persons entered into an agreement (the “Joint Filing Agreement”) in which the parties agreed to the joint filing on behalf of each of them of statements on Schedule 13D with respect to the securities of the Issuer to the extent required by applicable law. The Joint Filing Agreement is attached as an exhibit hereto and is incorporated herein by reference.
CUSIP No. 26658A 10 7 | SCHEDULE 13D | Page 13 of 14 |
| Item 7. | Material to be Filed as Exhibits. |
| Exhibit 4: | Investors Rights Agreement, dated December 11, 2009, by and among the Issuer and the holders of Common Stock issuable upon the Conversion listed in Schedule A thereto, the form of which was filed confidentially and incorporated herein by reference to Exhibit 10.6 to Amendment No.4 to the Issuer’s Registration Statement on Form S-1 (File No. 333- 180280), filed with the SEC on July 9, 2012. |
CUSIP No. 26658A 10 7 | SCHEDULE 13D | Page 14 of 14 |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: July 25, 2012
| AISLING CAPITAL III, LP | ||||
| By: | Aisling Capital Partners III, LP General Partner | |||
| By: | Aisling Capital Partners III LLC General Partner | |||
| By: | /s/ Dennis Purcell | |||
| Name: Dennis Purcell | ||||
| Title: Managing Member | ||||
| AISLING CAPITAL PARTNERS III, LP | ||||
| By: | Aisling Capital Partners III LLC General Partner | |||
| By: | /s/ Dennis Purcell | |||
| Name: Dennis Purcell | ||||
| Title: Managing Member | ||||
| AISLING CAPITAL PARTNERS III LLC | |||
| By: | /s/ Dennis Purcell | ||
Name: Dennis Purcell Title: Managing Member | |||
| /s/ Steve Elms | |||
| Steve Elms | |||
| /s/ Dennis Purcell | |||
| Dennis Purcell | |||
| /s/ Andrew Schiff | |||
| Andrew Schiff | |||
Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).